The association of transporter genes polymorphisms and lung cancer chemotherapy response

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Wang, Ying ^a   Yin, Ji Ye ^a   Li, Xiang Ping ^a   Chen, Juan ^a   Qian, Chen Yue ^a   Zheng, Yi ^a   Fu, Yi Lan ^b   Chen, Zi Yu ^b   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; AQUAPORIN 9; CARBOPLATIN; CISPLATIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE PROTEIN; ORGANIC CATION TRANSPORTER 2; ANTINEOPLASTIC AGENT; AQP2 PROTEIN, HUMAN; AQP9 PROTEIN, HUMAN; AQUAPORIN; ORGANIC CATION TRANSPORTER; SLC22A2 PROTEIN, HUMAN; TMEM205 PROTEIN, HUMAN;

ADULT; AGED; AQP2 GENE; AQP9 GENE; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; HUMAN; LRP GENE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OCT2 GENE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TMEM205 GENE; BIOLOGICAL MODEL; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AQUAPORIN 2; AQUAPORINS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MODELS, GENETIC; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84898605928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091967     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Wernyj RP, Morin PJ (2004) Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat 7: 227-232. (Pubitemid 39469095)
4. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392. (Pubitemid 38101633)
5. Shen DW, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64: 706-721.
6. Knepper MA, Wade JB, Terris J, Ecelbarger CA, Marples D, et al. (1996) Renal aquaporins. Kidney Int 49: 1712-1717. (Pubitemid 26188068)
7. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535. (Pubitemid 351738162)
8. Shen DW, Ma J, Okabe M, Zhang G, Xia D, et al. (2010) Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol 225: 822-828.
9. Shen DW, Gottesman MM (2012) RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res 29: 643-650.
10. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23. (Pubitemid 46137553)
11. Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H (2004) Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 66: 196-202. (Pubitemid 38870095)
12. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, et al. (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167: 1477-1484. (Pubitemid 41713303)
13. Wang W, Ke S, Chen G, Gao Q, Wu S, et al. (2004) Effect of lung resistancerelated protein on the resistance to cisplatin in human ovarian cancer cell lines. Oncol Rep 12: 1365-1370.
14. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, et al. (2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27: 2604-2614.
15. Efferth T, Volm M (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107: 155-176. (Pubitemid 40910039)
16. Campa D, Muller P, Edler L, Knoefel L, Barale R, et al. (2012) A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer 131: 2920-2928.
17. Xu X, Ren H, Zhou B, Zhao Y, Yuan R, et al. (2012) Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in nonsmall cell lung cancer (NSCLC) patients. Lung Cancer 77: 438-442.
18. Xu X, Duan L, Zhou B, Ma R, Zhou H, et al. (2012) Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese nonsmall cell lung carcinoma patients. Clin Exp Pharmacol Physiol 39: 786-792.
19. Zolk O, Solbach TF, Konig J, Fromm MF (2009) Functional characterization of the human organic cation transporter 2 variant p.270Ala.Ser. Drug Metab Dispos 37: 1312-1318.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
21. (2003) The International HapMap Project. Nature 426: 789-796.
22. Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM (2006) Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 95: 25-36.
23. Wright SH, Dantzler WH (2004) Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84: 987-1049. (Pubitemid 38823772)
24. Filipski KK, Loos WJ, Verweij J, Sparreboom A (2008) Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14: 3875-3880.
25. Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, et al. (2009) Smoking intensity, oxidative stress and chemotherapy in nonsmall cell lung cancer: a correlated prognostic study. Biosci Trends 3: 191-199.
26. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from ''never smokers'' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311. (Pubitemid 39209661)
27. Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, et al. (2006) Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24: 1700-1704. (Pubitemid 46622141)
28. Groves CE, Suhre WB, Cherrington NJ, Wright SH (2006) Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules. J Pharmacol Exp Ther 316: 743-752. (Pubitemid 43131002)
29. Alnouti Y, Petrick JS, Klaassen CD (2006) Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab Dispos 34: 477-482. (Pubitemid 43290907)
30. Slitt AL, Cherrington NJ, Hartley DP, Leazer TM, Klaassen CD (2002) Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab Dispos 30: 212-219. (Pubitemid 34106542)
31. Miao ZF, Chang EE, Tsai FY, Yeh SC, Wu CF, et al. (2009) Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells. Toxicol In Vitro 23: 209-216.
32. Onuki N, Wistuba, II, Travis WD, Virmani AK, Yashima K, et al. (1999) Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85: 600-607. (Pubitemid 29075281)
33. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, et al. (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764. (Pubitemid 28405625)
34. Eymin B, Gazzeri S, Brambilla C, Brambilla E (2001) Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 20: 1678-1687. (Pubitemid 32368015)
35. Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S (2003) p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 22: 1822-1835. (Pubitemid 36513141)
36. Kishore BK, Krane CM, Di Iulio D, Menon AG, Cacini W (2000) Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int 58: 701-711. (Pubitemid 30620019)
37. Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, et al. (2002) Cisplatinbased therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94: 173-181. (Pubitemid 34162751)
38. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (.55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457-462.
39. Lilenbaum RC, Herndon JE, 2nd, List MA, Desch C, Watson DM, et al. (2005) Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23: 190-196. (Pubitemid 41702638)